An Approach to Evaluating Antibacterial Agents in the Treatment of Urinary Tract Infection

The evaluation of antibacterial therapy for urinary tract infection (UTI) is based on the results of randomized, controlled comparative studies (preferably double-blinded) in which sufficient numbers of patients are entered into both arms to ensure statistical validity. Since the term UTI encompasse...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 1992-06, Vol.14 (Supplement-2), p.S246-S251
Main Authors: Rubin, Robert H., Beam, Thomas R., Stamm, Walter E.
Format: Article
Language:English
Subjects:
Acute Disease
Anti-Infective Agents, Urinary - therapeutic use
Antibacterials
Antibiotics
Antimicrobials
Bacteriuria
Bacteriuria - drug therapy
Humans
Infections
Pyelonephritis
Pyelonephritis - drug therapy
Symptoms
Urinary tract
Urinary tract infections
Urinary Tract Infections - drug therapy
Urine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The evaluation of antibacterial therapy for urinary tract infection (UTI) is based on the results of randomized, controlled comparative studies (preferably double-blinded) in which sufficient numbers of patients are entered into both arms to ensure statistical validity. Since the term UTI encompasses a broad array of clinical syndromes (acute uncomplicated UTI; acute uncomplicated pyelonephritis; complicated UTI; and asymptomatic bacteriuria), the design of clinical studies should include a careful definition of the clinical syndromes being studied, the course of therapy prescribed, and the microbiological characterization necessary for evaluability. End points to be considered in the evaluation of new therapies include the effect of therapy on clinical symptoms; the ability of the therapy to eradicate the original infecting organism; the incidence of reinfection posttherapy; the number of instances of primary drug resistance of the infecting inoculum; and the incidence of adverse effects with a particular regimen.
ISSN:1058-4838
1537-6591
DOI:10.1093/clinids/14.Supplement_2.S246